Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today ...
Alzheimer's disease Therapeutics Market. LAS VEGAS, NV, UNITED STATES, January 23, 2025 /EINPresswire / -- DelveInsight's“Acute Respiratory Distress Synd ...
In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...
The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Research from WashU Medicine found a possible new treatment strategy for certain types of blood cancers. The bone marrow of a mouse with a myeloproliferative neoplasm (left) shows fibrosis, or scar ...
The following is a summary of “Outcomes of Patients With Treated Secondary Acute Myeloid Leukemia: A High-Risk Subtype That Warrants an Independent Prognostic Designation,” published in the December ...
While the absolute risk of melanoma by age 40 remained low, survivors of childhood cancer exhibited a standardized incidence ...
A 41-year-old woman with no significant past medical history presents with a solitary nodule on her lower left ankle. The lesion has been growing over the past several months. The patient first ...
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you. Daily news – Get the most important news from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback